2024 Partners
Aldevron
Expertise Partner
Aldevron serves the biotechnology industry with custom production of nucleic acids and proteins. Thousands of clients use Aldevron-produced plasmids, RNA and gene editing enzymes for projects ranging from discovery research to clinical trials to commercial applications. These products are critical raw materials and key components in commercially available drugs and medical devices.
Aldevron is known for inventing the GMP-Source® quality system and for specializing in cGMP manufacturing, operating the world’s largest facility at its company headquarters in Fargo, North Dakota, with additional facilities in Madison, Wisconsin.
CRISPR QC
Program Partner
CRISPR QC leads the genomics frontier with its CRISPR Analytics Platform, driven by the proprietary CRISPR-Chip. This revolutionary technology offers real-time insights into CRISPR/Cas kinetics, enabling effective gene-editing. The platform's data provides researchers with unparalleled accuracy and reliability in evaluating CRISPR/Cas systems, optimizing efficiency, and advancing applications in therapeutics, agriculture, and beyond. In the fast-moving field of genomics, CRISPR QC provides indispensable data for informed gene-editing decisions.
Edilytics
Hosting Partner
Edilytics develops precision genome editing analysis software. Our flagship product, CRISPResso, quantifies editing events from NGS data. CRISPResso is the industry’s foremost quantification tool, with over 1,500 citations and wide adoption across academia and industry. CRISPResso enables your scientists to quickly and accurately characterize your nuclease with a biologically informed alignment algorithm. With support for Cas9, Prime Editing, Base Editing, and bespoke nucleases, CRISPResso is the standard for precision genome editing analytics.
Modalis Therapeutics
Industry Partner
Modalis Therapeutics, founded in 2016 and listed on the Tokyo Stock Exchange, is a forerunner in the field of epigenetic medicine. Modalis’ proprietary CRISPR GNDM technology is capable of specifically modulating the expression of disease-relevant genes without introducing double-strand DNA breaks, which has been validated in disease animal models and non-human primates studies.
Specializing in genetic disorders affecting the neuromuscular and CNS regions, Modalis’s flagship program, MDL101, aims to treat LAMA2-CMD, a severe congenital form of muscular dystrophy to which no effective therapy exists.
Sumitomo Chemical
Event Partner
Sumitomo Chemical is a leading provider of gRNA for therapeutic genome editing. At our brand-new, state-of-the-art cGMP facility in Japan, we deliver top-notch gRNA at unmatched purity levels - 100mer with 90% purity; 130mer with over 80% purity; 200mer and even longer gRNAs with world-class quality. Our standardized manufacturing method allows us to offer seamless scale up from lab to plant, at short lead time.
